© Drug Hunter Inc. 2018-2023
Home > GSK620
BD2 domain selective BET inhibitor
oral efficacy in 3 inflammation models
from SBDD of a BD2-selective HTS hit
Science, Mar. 19, 2020
GlaxoSmithKline, Stevenage, UK
GSK620 (GlaxoSmithKline (GSK) oral in vivo BD2 domain selective BET inhibitor)
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year